(S (S (VP (VBG Understanding) (NP (NP (DT the) (JJ temporal) (NNS dynamics)) (PP (IN of) (NP (NNP COVID-19) (NN patient) (NNS phenotypes)))))) (VP (VBZ is) (ADJP (JJ necessary)) (S (VP (TO to) (VP (VB derive) (NP (NP (JJ fine-grained) (NN resolution)) (PP (IN of) (NP (NN pathophysiology)))))))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBP use) (NP (JJ state-of-the-art) (JJ deep) (JJ neural) (NNS networks)) (PP (IN over) (NP (DT an) (JJ institution-wide) (NN machine) (NN intelligence) (NN platform))) (PP (IN for) (NP (NP (DT the) (JJ augmented) (NN curation)) (PP (IN of) (NP (NP (QP (CD 15.8) (CD million)) (JJ clinical) (NNS notes)) (PP (IN from) (NP (NP (CD 30,494) (NNS patients)) (VP (VBN subjected) (PP (TO to) (NP (NNP COVID-19) (NNP PCR) (JJ diagnostic) (NN testing))))))))))) (. .))
(S (PP (IN By) (S (VP (VBG contrasting) (NP (NP (DT the) (ADJP (NNP Electronic) (NNP Health) (NNP Record) (PRN (-LRB- -LRB-) (NNP EHR) (-RRB- -RRB-)) (VBD -derived)) (JJ clinical) (NNS phenotypes)) (PP (IN of) (NP (NP (NNP COVID-19-positive) (PRN (-LRB- -LRB-) (NP (NNP COVIDpos)) (, ,) (NP (NN n=635)) (-RRB- -RRB-))) (IN versus) (NP (NNP COVID-19-negative) (PRN (-LRB- -LRB-) (NP (NNP COVIDneg)) (, ,) (NP (NN n=29,859)) (-RRB- -RRB-)) (NNS patients))))) (PP (IN over) (NP (NP (DT each) (NN day)) (PP (IN of) (NP (NP (DT the) (NN week)) (VP (VBG preceding) (NP (DT the) (NNP PCR) (NN testing) (NN date)))))))))) (, ,) (NP (PRP we)) (VP (VBP identify) (NP (NP (NP (NP (JJ anosmia/dysgeusia)) (PRN (-LRB- -LRB-) (ADJP (JJ 37.4-fold)) (-RRB- -RRB-))) (, ,) (NP (NP (FW myalgia/arthralgia)) (PRN (-LRB- -LRB-) (ADJP (JJ 2.6-fold)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ diarrhea)) (PRN (-LRB- -LRB-) (ADJP (JJ 2.2-fold)) (-RRB- -RRB-))) (, ,) (NP (NP (NNS fever/chills)) (PRN (-LRB- -LRB-) (ADJP (JJ 2.1-fold)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ respiratory) (NN difficulty)) (PRN (-LRB- -LRB-) (NP (JJ 1.9-fold)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (NN cough)) (PRN (-LRB- -LRB-) (ADJP (JJ 1.8-fold)) (-RRB- -RRB-)))) (SBAR (IN as) (S (VP (ADVP (RB significantly)) (VBN amplified) (PP (IN in) (NP (NP (NNP COVIDpos)) (PP (IN over) (NP (NNP COVIDneg) (NNS patients)))))))))) (. .))
(S (NP (NP (DT The) (JJ specific) (NN combination)) (PP (IN of) (NP (NN cough) (CC and) (NN diarrhea)))) (VP (VP (VBZ has) (NP (DT a) (JJ 3.2-fold) (NN amplification)) (PP (IN in) (NP (NNP COVIDpos) (NNS patients))) (PP (IN during) (NP (NP (DT the) (NN week)) (ADVP (RB prior) (PP (TO to) (NP (NNP PCR) (NN testing))))))) (, ,) (CC and) (VP (ADVP (IN along) (PP (IN with) (NP (NN anosmia/dysgeusia)))) (, ,) (VBZ constitutes) (NP (NP (DT the) (JJS earliest) (JJ EHR-derived) (NN signature)) (PP (IN of) (NP (NNP COVID-19))) (PRN (-LRB- -LRB-) (ADVP (NP (JJ 4-7) (NNS days)) (RB prior) (PP (TO to) (NP (JJ typical) (NNP PCR) (VBG testing) (NN date)))) (-RRB- -RRB-))))) (. .))
(S (NP (DT This) (NN study)) (VP (VBZ introduces) (NP (NP (DT an) (JJ Augmented) (NN Intelligence) (NN platform)) (PP (IN for) (NP (NP (DT the) (JJ real-time) (NN synthesis)) (PP (IN of) (NP (NP (JJ institutional) (NN knowledge)) (VP (VBN captured) (PP (IN in) (NP (NNP EHRs)))))))))) (. .))
(S (NP (DT The) (NN platform)) (VP (VBZ holds) (NP (NP (JJ tremendous) (NN potential)) (PP (IN for) (S (VP (VBG scaling) (PRT (RP up)) (NP (NN curation) (NN throughput)) (, ,) (PP (IN with) (NP (NP (JJ minimal) (NN need)) (PP (IN for) (S (VP (VBG retraining) (NP (JJ underlying) (JJ neural) (NNS networks))))))))))) (, ,) (S (ADVP (RB thus)) (VP (VBG promising) (NP (JJ EHR-powered) (JJ early) (NN diagnosis)) (PP (IN for) (NP (NP (DT a) (JJ broad) (NN spectrum)) (PP (IN of) (NP (NNS diseases)))))))) (. .))
